V
Vera Mastey
Researcher at Regeneron
Publications - 31
Citations - 3393
Vera Mastey is an academic researcher from Regeneron. The author has contributed to research in topics: Dupilumab & Medicine. The author has an hindex of 10, co-authored 23 publications receiving 2408 citations.
Papers
More filters
Journal ArticleDOI
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson,Thomas Bieber,Emma Guttman-Yassky,Lisa A. Beck,Andrew Blauvelt,Michael J. Cork,Jonathan I. Silverberg,Mette Deleuran,Yoko Kataoka,Jean-Philippe Lacour,Külli Kingo,Margitta Worm,Margitta Worm,Yves Poulin,Andreas Wollenberg,Yuhwen Soo,Neil M.H. Graham,Gianluca Pirozzi,Bolanle Akinlade,Heribert Staudinger,Vera Mastey,Laurent Eckert,Abhijit Gadkari,Neil Stahl,George D. Yancopoulos,Marius Ardeleanu +25 more
TL;DR: Dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and depression, and quality of life, as compared with placebo in two phase 3 trials of identical design.
Journal ArticleDOI
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt,Marjolein S. de Bruin-Weller,Melinda Gooderham,Jennifer Clay Cather,Jamie Weisman,David M. Pariser,Eric L. Simpson,Kim A. Papp,H. Chih ho Hong,Diana Rubel,Peter Foley,Errol P. Prens,Christopher E.M. Griffiths,Takafumi Etoh,Pedro Herranz Pinto,Ramon M. Pujol,Jacek C Szepietowski,Karel Ettler,Lajos Kemény,Xiaoping Zhu,Bolanle Akinlade,Thomas Hultsch,Vera Mastey,Abhijit Gadkari,Laurent Eckert,Nikhil Amin,Neil M.H. Graham,Gianluca Pirozzi,Neil Stahl,George D. Yancopoulos,Brad Shumel +30 more
TL;DR: This 1-year, randomised, double-blinded, placebo-controlled, phase 3 study aimed to evaluate the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids versus placebo with topical cortiosteroids in adults with moderate-to-severe atopic dermatitis.
Journal ArticleDOI
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
Diamant Thaçi,Eric L. Simpson,Lisa A. Beck,Thomas Bieber,Andrew Blauvelt,Kim A. Papp,Weily Soong,Margitta Worm,Jacek C Szepietowski,Howard Sofen,M. Kawashima,Richard Wu,Steven P. Weinstein,Neil M.H. Graham,Gianluca Pirozzi,Ariel Teper,E. Rand Sutherland,Vera Mastey,Neil Stahl,George D. Yancopoulos,Marius Ardeleanu +20 more
TL;DR: Dupilumab improved clinical responses in adults with moderate-to-severe atopic dermatitis in a dose-dependent manner, without significant safety concerns, and shows that IL-4 and IL-13 are key drivers of atopic skinitis.
Journal ArticleDOI
Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults
Eric L. Simpson,Thomas Bieber,Laurent Eckert,Richard Wu,Marius Ardeleanu,Neil M.H. Graham,Gianluca Pirozzi,Vera Mastey +7 more
TL;DR: Adults with moderate to severe AD report multidimensional burden including disease activity, patient-reported symptoms, comorbidities, and quality-of-life impact.
Journal ArticleDOI
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
Gil Yosipovitch,M. Reaney,Vera Mastey,Laurent Eckert,A. Abbé,Lauren Nelson,M. Clark,N. Williams,Zhen Chen,Marius Ardeleanu,Bolanle Akinlade,N.M.H. Graham,Gianluca Pirozzi,Heribert Staudinger,S. Plaum,Allen Radin,Abhijit Gadkari +16 more
TL;DR: The Peak Pruritus Numerical Rating Scale (NRS) was developed and validated as a single‐item, patient‐reported outcome (PRO) of itch severity.